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Abstract
Background: Ewing Sarcoma Family Tumours (ESFT) are rare in early childhood. The aim of this study was to report the
clinical characteristics and outcome of children under 6 years of age affected by ESFT of the bone in Italy.
Methods: The records of all the children diagnosed with osseous ESFT in centres members of the Associazione Italiana di
Ematologia ed Oncologia Pediatrica (AIEOP) from 1990 to 2008 were reviewed. The Kaplan–Meier method was used for
estimating overall and progression-free survival (OS, PFS) curves; multivariate analyses were performed using Cox
proportional hazards regression model.
Results: This study includes 62 patients. An axial primary localization was present in 66% of patients, with the primary site in
the chest wall in 34%. Fourteen (23%) patients presented metastatic disease. The 5-year OS and PFS were 73% (95%
confidence interval, CI, 58–83%) and 72% (95% CI 57–83%) for patients with localized disease and 38% (95% CI 17–60%) and
21% (95% CI 5–45%) for patients with metastatic disease. Metastatic spread, skull/pelvis/spine primary localization,
progression during treatment and no surgery predicted worse survival (P,0.01), while patients treated in the last decade
had better survival (P = 0.002). In fact, the 5-year OS and PFS for patients diagnosed in the period 2000–2008 were 89%
(95% CI 71–96%) and 86% (95% CI 66–94%), respectively.
Conclusion: The axial localization is the most common site of ESFT in pre-scholar children. Patients treated in the most
recent period have an excellent outcome.
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Introduction
The Ewing Sarcoma Family Tumours (ESFT) are aggressive
neoplasms due to proliferation of small round cells of neuroecto-
dermal origin [1,2]. ESFT are biologically characterized by the
presence of a chimeric transcript, resulting from the fusion of the
EWS gene with genes that encode for structurally related
transcription factors, usually FLI1 or ERG 2 [3].
In 75% of cases, ESFT arise in bone and metastatic spread is
present at diagnosis in 25% of patients. ESFT represent the
second most common bone tumour in children and adolescents,
accounting for 3% of all paediatric tumours [1,2]. Significant
progress has been achieved in the diagnosis and treatment of
localised disease, over the past 30 years. Indeed, nowadays,
overall survival (OS) is approximately 70% for patients with
localized ESFT. However, OS still remains between 20% and
30% for patients with metastatic disease [1,2,4–6].
Poor outcome has also been reported to be associated with older
age at presentation (age §14 years or §18 years) [4,6,7], larger
tumour volume [6,8,9], poor response to induction therapy [6],
axial tumour localization [4,6], elevated serum levels of lactate
dehydrogenase [10], less than 90% necrosis after primary
chemotherapy [11], deletion of p16 [12] and mutation of p53
proteins [13,14].
Both ESFT and osteosarcoma tumours have their highest
incidence in late childhood/early adolescence, while occurrence in
early childhood is rare [15]. The aim of this study is to describe the
clinical characteristics and outcome of pre-scholar children
affected by ESFT of bone diagnosed and treated in centres
members of the Italian AIEOP (Associazione Italiana di
Ematologia Oncologia Pediatrica).
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Methods
The AIEOP database, to which all cases of tumours diagnosed
in member centres had to be routinely reported, was checked in
order to identify patients aged between 0 and 18 years affected by
ESFT of bone and diagnosed in the study period January 1990-
March 2008.
Patient selection was made on the basis of a diagnosis of
primitive bone tumour and a pathology compatible with ESFT;
they represented a series of consecutive diagnoses during the study
period. We excluded from analysis patients lacking a confirmatory
histological diagnosis.
Sixty-two patients, diagnosed before 6 years of age, were
identified and are included in the present analysis, the prevalence
of pre-scholar ESFT in the AIEOP series was 14.6%.
For the study purposes, medical records of patients were
retrospectively reviewed and data regarding gender, age, tumour
localization at diagnosis, presence of metastases, site of metastases,
tumour dimension, treatment protocol, degree of tumour necrosis
histologically assessed after surgery and outcome were collected.
An informed written consent was obtained from patients’
parents or legal guardians at the time of diagnosis. All the
therapeutic protocols were approved by local Institutional Review
Board (IRB) and performed in accordance with the Helsinki
declaration. This retrospective study was approved by the AIEOP
board and by the Ospedale Pediatrico Bambino Gesu` IRB.
Statistical Methods
OS was defined as the time interval between the date of
diagnosis and either the date of death from any cause or the date
of last follow-up. Progression-free survival (PFS) was defined as the
time interval between the date of diagnosis and the date of death,
first relapse/progression or the date of last follow-up. The
Kaplan–Meier method was used for the estimation of survival
curves [16], while the log-rank test was used to compare
differences between groups.
Multivariate analyses of variables potentially influencing OS
and PFS were performed using Cox proportional hazards
regression model. Variables that reached a P-value of 0.2 in
univariate analysis were included in the initial model and
variables were eliminated one at a time in a stepwise fashion,
only keeping variables that reached a P-value of 0.05 or less
into the final models. All P-values were 2-sided, with a type I
error rate fixed at 0.05. Variables considered in risk factor
analysis for OS and PFS were: the period of diagnosis (1990–
1999; 2000–2008), gender, primary site (extremities, chest wall
and other axial sites), presence of metastases, site of metastases
(lung only, combined), tumour size (,8 cm, $8 cm), response
to primary chemotherapy, surgery on primary tumour (yes/no),
definitive surgery (yes/no); radiotherapy on primary tumour
(yes/no); type of local control (none, radiotherapy alone, surgery
alone, surgery plus radiotherapy) and necrosis after chemother-
apy and surgery (100% or less than 100%). The cut-off for
tumour size ,8 cm/$8 cm was chosen in view of the data
published by Rodriguez Galindo et al. [4]. Definitive surgery
was codified according to Krasin et al. [17]. Analyses were
performed using the Stata 9.0 statistical software package
(StatCorp LP, TX, USA).
Results
Patients and Treatment
Clinical characteristics of the 62 patients with bone ESFT and
younger than 6 years are summarized in Table 1.
The median age at diagnosis was 42 months (range 5–70), 82%
of patients being older than 24 months. The presenting symptoms
were pain (32%), palpable lesion (36%), walking disorder or
neurologic impairment (32%), respiratory symptoms (19%) and
fever or/and anorexia (8%).
Forty-three patients were prospectively enrolled in the national
protocols ongoing at the time of diagnosis; 10 patients were treated
at the Fondazione IRCCS Istituto Nazionale dei Tumori (INT) in
Milan, and 9 patients at the Ospedale Pediatrico Bambino Gesu`
(OPBG) in Rome with institutional protocols [18–21]. All
protocols were based on cyclophosphamide, doxorubicin, ifosfa-
mide, plus vincristine and/or actinomycin D. The main difference
was the addition of etoposide in the more recent period. The INT
protocol used cisplatin without doxorubicin, while the OPBG
protocol used carboplatin.
Most patients (66%) had an axial primary tumour, with 34%
having a chest wall primary localization; the prevalence of axial
involvement was 75% and 57% in patients with either localized or
metastatic disease, respectively (P = NS).There were no difference
regarding the site distribution of primary tumours according to the
period group: an axial primary tumour was diagnosed in 21/32
(67%) patients in the 1990–1999 period and in 21/30 (69%)
patients in the later period 2000–2008.
Fourteen (23%) patients presented metastatic spread at di-
agnosis. According to primary site, metastatic disease was evident
in 30% of patients with ESFT of the extremity, 14% of patients
with ESFT of the chest wall and 25% of patients with ESFT of
axial sites other than chest wall (P = NS).
Nearly all patients (90%) received a local treatment at the site of
primary tumour: it was surgery alone in 30 patients (48%);
radiotherapy alone in 8 (13%) and surgery plus radiotherapy in 18
(29%).
Radical surgery was performed at diagnosis in 5 patients. Of the
remaining 57, 56 were evaluable for response to primary
chemotherapy and 6 of them progressed during chemotherapy.
Out of these 6 patients who progressed during induction
chemotherapy, 3 children underwent surgical removal of the
primary tumour, while palliative radiotherapy was administered in
one patient.
The radiotherapy dose was different according to primary site,
ranging from 35 Gy to 60.4 Gy; 4 patients with lung metastases
received whole lung irradiation at a dose of 12 Gy.
Twenty-four patients (39%) received myeloablative chemother-
apy followed by autologous hematopoietic stem cell transplanta-
tion as consolidation therapy; 9 of them were affected by ESFT of
the chest wall.
Outcome and Analysis of Prognostic Factors
The median follow-up of the entire cohort was 62 months
(range 1 month-25 years). Of the 62 patients, 20 (32%) died, 19 of
relapsed/resistant disease and one patient of treatment-related
complications after the second course of chemotherapy.
Secondary malignancies were not recorded.
Relapse/progression occurred in 25/62 (40%) patients after
a median time from diagnosis of 19 months (range 2–121 months).
Fourteen patients with localized disease (29%) experienced
a relapse/progression, at a median time from diagnosis of 20
months (range 2–121 months), and 11 of them died. In the
subgroup of patients with metastatic disease, 11/14 (79%) patients
relapsed/progressed after a median time from diagnosis of 17
months (range 3–32 months) and 8 of them died due to disease
progression.
Tables 1 and 2 summarize the results of univariate analysis of
factors influencing patients’ outcome. Metastatic spread at time of
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diagnosis, combined metastasis and a primary tumour localized in
the skull, pelvis or spine were found to be associated with worse
OS and/or PFS.
The 5-year Kaplan-Meier estimates of OS and PFS for patients
with localized disease were 73% (95% confidence interval CI 58–
83%) and 72% (95% CI 57–83%), respectively. The 5-year
Kaplan-Meier estimates of OS and PFS for patients with
metastatic disease was 38% (95% CI 17–60%) and 21% (95%
CI 5–45%), respectively. The difference in OS and PFS between
the two patient groups was statistically significant (P,0.01). The 5-
year OS and PFS for patients with primary chest localization were
89% (95% CI 63–97%) and 73% (95% CI 46–88%), respectively,
while the 5-year OS and PFS for other axial sites were 45% (95%
CI 23–65%) and 39% (95% CI 17–61%), respectively and those
for patients with a primary localization at the extremities were
73% (95% CI 47–88%) and 68% (95% CI 43–84%), respectively.
The differences in OS and PFS between the groups were
statistically significant (P,0.05. see also figure 1, 2, 3, 4).
The OS of all AIEOP patients with ESFT, irrespectively of age,
was 60% (95% CI 57–63) for patients with localized disease, 32%
(95% CI 28–36) for patients with metastatic disease and 53% (95%
CI 46–59) for patients with primary chest tumour. In our cohort of
children below the age of 6, patients affected by primary chest wall
involvement presented an excellent outcome; this favourable
outcome is probably due to a limited proportion of patients with
metastatic spread and an aggressive strategy for local control.
Indeed, surgery plus radiotherapy was employed in 38% of
Table 1. Patient characteristics and univariate analysis of pre-treatment predictive factors.
N % PFS 5 yr 95% CI P Value OS 5 yr 95% CI P Value
Median Age 42 months (5–70) % %
Gender Male 28 45 58 39–73 0,069 67 48–80 0,067
Female 34 55 63 44–76 64 46–77
Stage of disease Localized 48 77 72 57–83 ,0.0001 73 58–83 0.002
Metastatic 14 23 21 5–45 38 17–60
Site of Metastasis Lung only 10 71 50 21–74 ,0.02 58 27–80 0.140
Combined 4 29 0 17 12–52
Tumor Size ,8 cm 23 68 65 35–84 0.440 76 47–90 0.489
$8 cm 11 32 65 37–82 81 51–90
Primary Sites Extremity 20 32 68 43–84 0.043 73 47–88 0.002
Chest Wall 21 34 73 46–88 89 63–97
Axial Sites (other than
chest wall)
21 34 39 17–61 45 23–65
doi:10.1371/journal.pone.0053223.t001
Table 2. Univariate analysis of treatment predictive factors.
n PFS 5 yr 95% CI
Univariate
analysis OS 5 yr 95% CI Univariate analysis
% p value % p value
Treatment Period 1990–1999 32 38 21–55 ,0.001 48 30–64 0.002
2000–2008 30 86 66–94 89 71–96
Histological Response 100% necrosis 15 87 56–96 0.3562 100 0.058
,100% 15 68 36–87 72 34–90
Surgery No 14 17 3–42 ,0.001 21 5–45 ,0. 001
Yes 46 74 58–85 83 68–92
Definitive Surgery No 25 42 22–61 0.002 42 22–60 ,0. 001
Yes 35 75 56–87 87 69–95
Response to CT PD 6 0 ,0.0001 0 ,0. 001
No PD 49 68 52–79 75 59–85
Local Control None 4 0 ,0.001 25 1–66 ,0. 001
RT alone 8 29 4–61 25 4–56
Surgery alone 30 72 52–85 82 62–92
Surgery plus RT 18 69 40–86 75 46–90
Legend: PD, progression of the disease; CT, Chemotherapy; RT, radiotherapy.
doi:10.1371/journal.pone.0053223.t002
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patients and more than 40% of children received high dose
chemotherapy (see Table 3 and 4 for details).
The treatment period (1990–1999 versus 2000–2008) influenced
outcome (see Figures 5 and 6). In fact, although there were no
statistically significant differences between the two groups in terms
of metastatic spread (28% in the 1990–1999 period versus 17% in
the later period, P = 0.3), the outcome of children treated in the
more recent period was better. In detail, the 5-year OS and PFS
for patients diagnosed in the period 2000–2008 was 89% (95% CI
71–96%) and 86% (95% CI 66–94%), respectively, while in the
previous period the 5-year OS and PFS were 48% (95% CI 30–
64%) and 38% (95% CI 21–55%), respectively (P,0.01 for both
Figure 1. Overall Survival (OS) according to stage (localized or metastatic disease).
doi:10.1371/journal.pone.0053223.g001
Figure 2. Progression Free Survival (PFS) according to stage (localized or metastatic disease).
doi:10.1371/journal.pone.0053223.g002
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Figure 3. Overall Survival (OS) according to primary site.
doi:10.1371/journal.pone.0053223.g003
Figure 4. Progression Free Survival (PFS) according to primary site.
doi:10.1371/journal.pone.0053223.g004
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OS and PFS). The treatment attitude throughout the two periods
analyzed was different. Indeed, in the first period surgery was
performed in 67% of patients while in the more recent period, this
percentage rose up to 94% (P = 0.002). Also the general strategy
for disease control was different with a clear evidence of a more
aggressive and a multi-modality approach based on conventional
chemotherapy, combined surgery and radiotherapy (Table 5). As
expected, the surgical and local control approach was different
according to primary site; surgery alone was used in 70% of
extremity primary and this percentage falling down to 29% in
patients affected by primary axial site (other than chest wall) (see
Table 4 for details about local control strategy by primary site).
In univariate analysis, surgery represented a major favourable
prognostic factor for both survival and recurrence (P,0.01).
Patients who received treatment with surgery or surgery plus
radiotherapy were found to have better outcomes than those who
were treated with radiotherapy alone (P,0.01). As expected,
progressive disease during first-line treatment represented a major
adverse prognostic factor (Table 6).
In the final model of multivariate analysis, the presence of
metastasis and a primary tumour of spine, skull or pelvis were poor
prognostic factors for both OS and PFS. Of the several treatment-
related variables found to predict outcome in univariate analysis,
only progression during first-line chemotherapy remained signif-
icant in multivariate analysis (Table 6).
Discussion
Bone tumours are rare in pre-scholar children. In a series of
1474 paediatric bone tumours, patients under the age of 6
accounted for only 5,8% [22].
Ewing Sarcoma represents the second most frequent bone
tumour after osteosarcoma: the highest incidence was observed in
late childhood and adolescence [15]. Two recent papers presented
clinical data and outcome of pre-scholar children affected by
osteosarcoma: in both papers, the authors reported a peculiar
histological pattern and an higher incidence of mutilating surgery
in younger patients, while the outcome was not statistically
different from that of older children [23–24].
The incidence of ESFT in early childhood is rare, accounting
for less than 10 cases per million each year, while the incidence of
this neoplasm is about 30–40 cases per million between 11 and 18
years of age [15]. In a recent paper, the ESFT rate in different
paediatric age groups was presented: no case was reported in the
first year of age while the incidence rate between 1 and 6 years
ranged from 0.99 to 2.04 per million of children (22). In view of
this observation, it is not surprising that data about the clinical
characteristics and outcome of ESFT in early childhood were
limited.
The aim of this study was to report on the clinical characteristics
and outcome of pre-scholar children affected by bone ESFT in
Table 4. Type of local control according to primary site of the tumour.
Pt None Surgery Alone RT alone Surgery plus RT
Extremity 20 5,0% 70,0% 5,0% 20,0%
Chest Wall 21 4,7% 57,0% 0,0% 38,0%
Axial Sites (other than chest wall) 21 4,7% 29,0% 33,0% 28,6%
doi:10.1371/journal.pone.0053223.t004
Figure 5. Overall Survival (OS) according to the period of diagnosis.
doi:10.1371/journal.pone.0053223.g005
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Italy. The main study limitation is the retrospective analysis
carried out on a population diagnosed over a long period of time
and treated according to different protocols in several paediatric
centres. Moreover, the tumour size and data on tumour
dimensions were available only in about 70% of patients (44/62)
and had been recorded with different imaging tools (either CT or
MRI). The criterion of 100% necrosis vs. less than 100% was
chosen in order to limit the differences in the evaluation within the
AIEOP pathology panel. Nevertheless, considering the low
occurrence rate of bone ESFT in pre-scholar children, we believe
that the present study provides useful information on a rare
subgroup of patients.
In the AIEOP experience, the prevalence of bone ESFT
diagnosed before the age of 6 years was 14.6% of all paediatric
ESFT patients (i.e. aged less than 18 years); this finding may be
influenced by the fact that we collected data only from paediatric
centres and we cannot exclude that some of the older patients with
ESFT have been referred to Institutions not reporting to AIEOP.
In this cohort, most patients had an axial primary localization
(66%, for the whole group, being 75% and 57% in patients with
either localized or metastatic disease, respectively), while, in other
series the axial site represents only 50% [7–9,18,24–26] of cases.
As observed in infants [27], the axial site seems to be a peculiar
characteristic of younger age. Recently, Van den Berg reported
a series of 14 infants: all patients had an axial tumours and most of
them had peripheral neuroectodermal tumours (PNETs) [27].
Also chest wall tumours seem to be characteristic of younger
age: we found a prevalence of 34%, while a prevalence of less than
20% has been reported [7–9;18,25–26]. Pelvis tumours occurred
in only 11% of patients and, as observed in a large series, the
incidence of pelvis tumours increases with age [26].
The outcome of our cohort, both in terms of OS and PFS. is
comparable with that observed in older patients. In literature, age
at diagnosis emerges as a significant prognostic factor for ESFT
[4,6,7,26] as also recently observed in multifocal disseminated
ESFT patients enrolled in EUROEWING 99 Protocol [28] and
age was considered in the risk stratification proposed by Rodriguez
Galindo [4].
Survival showed an impressive improvement in the last decade,
with OS exceeding 85% in comparison with a value of less than
50% of the previous decade (P,0.002), considering both localized
and metastatic patients. The two groups presented comparable
clinical features: in particular, there were no differences in term of
metastatic spread and/or primary tumour site, while a difference
in strategy was clearly evident between the two time periods. The
favourable outcome achieved in the last decade is possibly due to
a multi-disciplinary and more aggressive strategy based on surgery
and radiotherapy. Moreover, a more aggressive surgical approach
is observed in the recent period: in the group 2000–2008, 94% of
patients underwent surgical removal of primary tumour, while
surgery was performed in 67% of patients in the group 1990–
1999.
In selected case conventional chemotherapy followed by high-
dose treatment and stem cell support as consolidation treatment
was used, while exclusive radiotherapy as local treatment was
deserved only to very few cases. Pelvic localization, poor
histological response, metastases, surgery, quality of local control
Figure 6. Progression Free Survival (PFS) according to the period of diagnosis.
doi:10.1371/journal.pone.0053223.g006
Table 5. Treatment strategy by Treatment Period.
Treatment Period 1990–1999 2000–2008
% %
CT 10 3
CT plus RT 23 3
CT plus Surgery 50 50
CT plus Surgery and RT 17 44
Legend: CT, chemotherapy, RT, radiotherapy.
doi:10.1371/journal.pone.0053223.t005
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of disease and response to treatment have been reported to
influence the outcome [4,6–9,11,25,26].
In our cohort, the site of primary tumour and the presence of
metastases resulted to have an impact on survival in the
multivariate analysis. In contrast to the results reported by Van
den Berg et al. [27], our data confirm the role of the previously
reported prognostic factors [4,6–11]. Furthermore, our data
indicate that a favourable outcome is presently attainable both
in younger patients affected by non-metastatic ESFT and in chest
ESFT with an aggressive treatment strategy. In the present series,
the chest wall primary represents a third of the population with an
excellent outcome, probably due to an aggressive strategy based on
surgery plus radiotherapy for local control and high-dose
chemotherapy.
A further prospective analysis on a larger number of patients
with localized or metastatic ESFT, homogeneously enrolled in the
most recent protocols, should answer the question whether age
does or does not have a prognostic value, independently from its
association with other variables predicting a poor outcome.
Moreover, further studies are warranted to provide information
on the biological aspects and to possibly explain the different
pattern of primary tumour localization.
Conclusion
ESFT is confirmed to be a rare tumour in early childhood. In
the AIEOP experience about 15% of affected children are younger
than 6 years of age while the axial -in particular chest- localization
is the most common primary site. In this group, the role of
previously reported prognostic factors was confirmed and
a favourable outcome is attainable with an aggressive strategy.
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